Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2007 1
2008 1
2009 1
2010 1
2011 4
2012 4
2013 4
2014 3
2015 2
2016 5
2017 3
2019 2
2021 2
2022 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes.
Peng T, Phasouk K, Sodroski CN, Sun S, Hwangbo Y, Layton ED, Jin L, Klock A, Diem K, Magaret AS, Jing L, Laing K, Li A, Huang ML, Mertens M, Johnston C, Jerome KR, Koelle DM, Wald A, Knipe DM, Corey L, Zhu J. Peng T, et al. Front Immunol. 2021 Sep 6;12:735643. doi: 10.3389/fimmu.2021.735643. eCollection 2021. Front Immunol. 2021. PMID: 34552595 Free PMC article.
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.
Ford ES, Li A, Laing KJ, Dong L, Diem K, Jing L, Basu K, Ott M, Tartaglia J, Gurunathan S, Reid JL, Ecsedi M, Chapuis AG, Huang ML, Magaret AS, Johnston C, Zhu J, Koelle DM, Corey L. Ford ES, et al. medRxiv [Preprint]. 2024 Feb 1:2022.02.04.22270210. doi: 10.1101/2022.02.04.22270210. medRxiv. 2024. Update in: JCI Insight. 2024 Jun 18;9(14):e179010. doi: 10.1172/jci.insight.179010 PMID: 38352384 Free PMC article. Updated. Preprint.
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.
Koelle DM, Magaret A, McClurkan CL, Remington ML, Warren T, Teofilovici F, Wald A. Koelle DM, et al. Clin Vaccine Immunol. 2008 May;15(5):773-82. doi: 10.1128/CVI.00020-08. Epub 2008 Mar 19. Clin Vaccine Immunol. 2008. PMID: 18353920 Free PMC article. Clinical Trial.
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L. Baeten JM, et al. J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013. J Infect Dis. 2011. PMID: 21148504 Free PMC article.
36 results